{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T14:42:50.318077",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 92,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "mortality",
        "treatment-related mortality",
        "fatal adverse events",
        "long-term survival",
        "median survival (by HCC stage)",
        "perioperative mortality",
        "mortality rate",
        "improved survival",
        "survival"
      ],
      "response_measures": [
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST)",
        "objective response rate (ORR)",
        "tumor response rate",
        "tumour response rate",
        "response rates (RECIST criteria for locoregional therapies)",
        "response rates (mRECIST for systemic therapy)",
        "response rates (RECIS systems for systemic therapy)",
        "response assessment (multiphase computed tomography with contrast)",
        "response assessment (magnetic resonance imaging with contrast)",
        "response rates",
        "objective tumour response",
        "partial response (PR)",
        "partial response",
        "complete response (CR)",
        "complete remission",
        "minor response (reduction of tumour size by 25 to 50%)",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "clinical benefit rate (CBR)",
        "clinical benefit rate",
        "local tumour control",
        "success rate (downstaging/bridging)",
        "tumor reduction",
        "recurrence",
        "disease recurrence",
        "recurrence detection"
      ],
      "progression_measures": [
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (modified RECIST)",
        "progression-free survivorship",
        "time to progression (TTP)",
        "time to progression (TTP; time from randomization to disease progression)",
        "time to progression of the tumor",
        "time to progression",
        "time to tumour progression",
        "time to symptom progression",
        "time to symptomatic progression (TTSP)",
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "time to deterioration",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 fitness subscale)",
        "time to clinically meaningful worsening of EQ-5D",
        "time to clinically meaningful deterioration of EORTC QLQ-C30 domains",
        "time to clinically meaningful deterioration of EORTC QLQ-HCC18 domains",
        "progression assessment (BCLC assessment system)"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse events (Grade ≥ 3)",
        "adverse reactions",
        "adverse reactions of grade 3 or higher",
        "treatment-emergent adverse events (TEAE)",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "complications",
        "post-treatment complications",
        "intraoperative complications",
        "long-term treatment-related complications",
        "complication incidence",
        "grade 3 adverse events",
        "grade 4 adverse events",
        "grade 5 adverse events",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "adverse events leading to discontinuation",
        "treatment-related deaths",
        "toxicity",
        "hepatotoxicity",
        "liver failure",
        "bleeding",
        "haemorrhagic events",
        "thromboembolic events",
        "ischaemic stroke",
        "respiratory failure",
        "sudden death",
        "secondary cancer",
        "leukaemia",
        "portal vein thrombosis",
        "gallbladder abscess",
        "postoperative softening",
        "nutrition",
        "weight loss",
        "loss of appetite",
        "decreased appetite",
        "fatigue",
        "fatigue (EORTC QLQ-HCC18)",
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "abdominal pain",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever",
        "fever (EORTC QLQ-HCC18)",
        "diarrhoea",
        "nausea",
        "neutropenia",
        "hand-foot skin reaction",
        "hand feeding reactions",
        "skin rash",
        "rash",
        "skin desquamation",
        "desquamation",
        "hypody",
        "hypothyroidism",
        "hypertension",
        "lymphoedema",
        "alopecia",
        "back pain",
        "limb pain",
        "joint pain",
        "cough",
        "dyspnoea",
        "pleural effusion",
        "increased ALT activity",
        "ALT increase",
        "AST increase",
        "creatinine increase",
        "hypocalcaemia",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography",
        "vital signs"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "treatment-related deaths",
        "fatal adverse events"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ-5D VAS",
        "EQ VAS (Euro QoL visual analogue scale)",
        "European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS)",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hep",
        "EORTC QLQ-30",
        "overall quality of life (measured with a validated and reliable instrument)"
      ],
      "functional_status": [
        "Eastern Cooperative Oncology Group Performance Status (ECOG PS)",
        "function scales of EORTC QLQ-C30",
        "function scales of EORTC QLQ-HCC18",
        "fitness subscale (EORTC QLQ-C30)",
        "functional role subscale (EORTC QLQ-C30)",
        "body image"
      ],
      "symptom_measures": [
        "fatigue (EORTC QLQ-HCC18)",
        "pain (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "nutrition",
        "pain",
        "fatigue",
        "nausea",
        "diarrhoea"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-benefit analysis"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "number needed to harm (NNH)",
        "number needed to treat (NNT)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "prognosis (tumour stage at diagnosis)",
        "prognosis (severity of underlying liver disease)",
        "prognosis (patient performance status)",
        "tumour spread (TNM system)",
        "progression assessment (BCLC assessment system)",
        "response assessment (multiphase computed tomography with contrast)",
        "response assessment (magnetic resonance imaging with contrast)",
        "recurrence detection"
      ],
      "biomarkers": [
        "blood and tumour biomarkers correlated with clinical outcomes",
        "pharmacokinetic parameters",
        "plasma pharmacokinetics lenvatinib exposure parameters"
      ]
    }
  }
}